# Lenalidomide in Treating Patients With High Risk Acute Myeloid Leukemia in Remission

> **NCT02126553** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 29 (actual)

## Conditions studied

- Alkylating Agent-Related Acute Myeloid Leukemia
- Secondary Acute Myeloid Leukemia

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT02126553
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11-13
- **Primary completion:** 2021-11-30
- **Final completion:** 2021-11-30
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2022-11-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02126553

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02126553, "Lenalidomide in Treating Patients With High Risk Acute Myeloid Leukemia in Remission". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02126553. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*